A Double-Blind, Randomized, Parallel Clinical Study to Evaluate the Efficacy and Safety of Nasal Spray in Adult Subjects With Symptoms of Common Cold

ITC Life Sciences and Technology Centre0 sites120 target enrollmentStarted: TBDLast updated: October 17, 2022

Trial Snapshot

No summary available.

•1.Subject in an early stage of a common cold with symptoms evidenced less than 48 hours. TSS at baseline less than 9 and a score of greater than 1 for at least one of the following symptoms: sore throat, runny nose or blocked nose.
•2.Subject who agrees to refrain from taking any products intended to prevent, intervene in, or treat
•cough, colds, flu during the study period.
•3. Female subject who is non-pregnant, non-lactating, postmenopausal, surgically sterilized, or using a medically acceptable form of birth control, as determined by the investigator.
•4. Subject willing to give informed consent and comply with the study procedures.

•1. Subjects with History of Clinically significant Disorder
•2.Subject having tested positive for SARS-CoV-2 by Rapid antigen testing on a nasopharyngeal or
•oropharyngeal swab during the screening visit.
•3.Subjects who test negative for viral load (Rhino virus, Influenza A, B, Human Coronavirus) at baseline.
•4.Subjects categorized with severe symptoms.
•5. Subject having taken influenza vaccination within the last 3 months prior to Screening visit.
•6.Subject having common cold or flu like symptoms for more than 48 hours.
•7. Subject under regular use of products that may influence the study outcome
•8. Pregnant and lactating women.
•9. Subjects allergic to herbal products or any component of the study product.
•10. Subjects currently participating or having participated in another clinical trial during the last 3 months prior to the beginning of this study.
•11.Any additional conditions that in the Investigators opinion would warrant exclusion from the study or prevent the subject from completing the study

Sponsor

ITC Life Sciences and Technology Centre